Announced on its homepage: “Read more Biofidelity raises $24 million in new financing to accelerate commercialization and expand product pipeline CAMBRIDGE, UK and R…”.
Observed on the company’s website; business claims are not independently verified.
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
How it described itself
Biofidelity Ltd
High sensitivity molecular assays for detection of genetic abnormalities with simple workflow and fast time-to-result, without the need for DNA sequencing.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
January 2025 – November 2026 · 5 captures · latest observed messagingThe power of simple.
5 November 2026 · The power of simple.current websiteHistorical capture not publicly available
January 2023 – July 2024 · 2 capturesWe've reshaped the future of genomics
Unleashing the potential of genomics to transform the world we live in through transformational technologies that remove the noise from genomic analysis.
5 January 2023 · We've reshaped the future of genomicsarchived page
3 July 2024 · We've reshaped the future of genomicsarchived page
Seen July 2021 · 1 captureRevolutionising cancer diagnostics
High sensitivity molecular assays for detection of genetic abnormalities with simple workflow and fast time-to-result, without the need for DNA sequencing.
High sensitivity molecular assays for detection of genetic abnormalities with simple workflow and fast time-to-result, without the need for DNA sequencing.